Cervical cancer is the fourth most common cancer in women worldwide, and prognosis is poor for those who experience recurrence or develop metastatic disease, in part due to the lack of active therapeutic directions. The National Cancer Institute convened a Cervical Cancer Clinical Trials Planning Meeting in October 2018 to facilitate the design of hypothesis-driven clinical trials focusing on locally advanced, metastatic, and recurrent cervical cancer around the theme of enhancing susceptibility to DNA repair inhibition and DNA damage. Before the meeting, a group of experts in the field summarized available preclinical and clinical data to identify potentially active inducers and inhibitors of DNA. The goals of the Clinical Trials Planning Meeting focused on identification of novel experimental strategies capitalizing on DNA damage and repair (DDR) regulators and cell cycle aberrations, optimization of radiotherapy as a DDR agent, and design of clinical trials incorporating DDR regulation into the primary and recurrent or metastatic therapies for cervical carcinoma. Meeting deliverables were novel clinical trial concepts to move into the National Clinical Trials Network. This report provides an overview for the rationale of this meeting and the state of the science related to DDR regulation in cervical cancer.

中文翻译：

---

NCI临床试验规划会议报告：子宫颈癌的发展：增强对DNA修复抑制和损伤的敏感性

宫颈癌是全世界女性中第四大最常见的癌症，部分复发或发生转移性疾病的妇女预后较差，部分原因是缺乏有效的治疗方向。美国国家癌症研究所于2018年10月召开了子宫颈癌临床试验计划会议，以促进以假说为驱动力的临床试验的设计，该试验的重点是增强对DNA修复抑制和DNA损伤的敏感性的局部晚期，转移性和复发性宫颈癌。在会议之前，该领域的专家小组总结了可用的临床前和临床数据，以鉴定潜在的DNA活性诱导剂和抑制剂。临床试验计划会议的目标集中在利用DNA损伤和修复（DDR）调节剂和细胞周期畸变的新颖实验策略的识别，优化放射治疗作为DDR药剂以及设计将DDR调节纳入主要和临床研究的临床试验中宫颈癌的复发或转移疗法。会议可交付成果是进入国家临床试验网络的新颖临床试验概念。本报告概述了本次会议的原理以及与宫颈癌中DDR调节有关的科学现状。会议可交付成果是进入国家临床试验网络的新颖临床试验概念。本报告概述了本次会议的原理以及与宫颈癌中DDR调节有关的科学现状。会议可交付成果是进入国家临床试验网络的新颖临床试验概念。本报告概述了本次会议的原理以及与宫颈癌中DDR调节有关的科学现状。